SAN DIEGO, May 5, 2014 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will
provide a corporate update and report first quarter 2014 financial
results after the NASDAQ Global Select Market closes on
Monday, May 12, 2014. That same day,
Arena will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
The conference call may be accessed by dialing 877.643.7155 for
domestic callers and 914.495.8552 for international callers. Please
specify to the operator that you would like to join the "Arena
Pharmaceuticals' First Quarter 2014 Financial Results Call." The
conference call will be webcast live under the investor relations
section of Arena's website at www.arenapharm.com, and will be
archived there for 30 days following the call. Please connect to
Arena's website several minutes prior to the start of the broadcast
to ensure adequate time for any software download that may be
necessary.
About Arena Pharmaceuticals
Arena is embracing the challenge of improving health by seeking
to bring innovative medicines targeting G protein-coupled receptors
to patients. BELVIQ® (lorcaserin HCl), Arena's
internally discovered drug, is approved in the United States and is under review for
regulatory approval in additional territories. Arena's US
operations are located in San Diego,
California, and its operations outside of the United States, including its commercial
manufacturing facility, are located in Zofingen, Switzerland. For more information, visit
Arena's website at www.arenapharm.com.
Arena Pharmaceuticals® and Arena® are
registered service marks of Arena Pharmaceuticals, Inc.
BELVIQ® is a registered trademark of Arena
Pharmaceuticals GmbH.
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. Such
forward-looking statements include statements about embracing the
challenge of improving health; seeking to bring innovative
medicines to patients; the regulatory review and approval of
BELVIQ; and Arena's focus, plans, goals, strategy, expectations,
research and development programs, and ability to discover and
develop compounds and commercialize drugs. For such statements,
Arena claims the protection of the Private Securities Litigation
Reform Act of 1995. Actual events or results may differ materially
from Arena's expectations. Factors that could cause actual results
to differ materially from the forward-looking statements include,
but are not limited to, the following: risks related to
commercializing drugs, including regulatory, manufacturing, supply
and marketing issues and the availability and use of BELVIQ; cash
and revenues generated from BELVIQ, including the impact of
competition; Arena's revenues will be based in part on estimates,
judgment and accounting policies, and incorrect estimates or
disagreement regarding estimates or accounting policies may result
in changes to Arena's guidance or previously reported results; the
timing and outcome of regulatory review is uncertain, and BELVIQ
may not be approved for marketing when expected or ever in
combination with another drug, for another indication or using a
different formulation or in any other territory for any indication;
regulatory decisions in one territory may impact other regulatory
decisions and Arena's business prospects; government and commercial
reimbursement and pricing decisions; risks related to relying on
collaborative arrangements; the timing and receipt of payments and
fees, if any, from collaborators; the entry into or modification or
termination of collaborative arrangements; unexpected or
unfavorable new data; nonclinical and clinical data is voluminous
and detailed, and regulatory agencies may interpret or weigh the
importance of data differently and reach different conclusions than
Arena or others, request additional information, have additional
recommendations or change their guidance or requirements before or
after approval; data and other information related to any of
Arena's research and development may not meet regulatory
requirements or otherwise be sufficient for (or Arena or a
collaborator may not pursue) further research and development,
regulatory review or approval or continued marketing; Arena's
ability to obtain and defend patents; the timing, success and cost
of Arena's research and development; results of clinical trials and
other studies are subject to different interpretations and may not
be predictive of future results; clinical trials and other studies
may not proceed at the time or in the manner expected or at all;
having adequate funds; and satisfactory resolution of litigation or
other disagreements with others. Additional factors that could
cause actual results to differ materially from those stated or
implied by Arena's forward-looking statements are disclosed in
Arena's filings with the Securities and Exchange Commission. These
forward-looking statements represent Arena's judgment as of the
time of this release. Arena disclaims any intent or obligation to
update these forward-looking statements, other than as may be
required under applicable law.
Contact: Arena
Pharmaceuticals, Inc.
|
Media Contact: Russo
Partners
|
|
|
Craig M. Audet,
Ph.D., Senior Vice President,
|
David Schull,
President
|
Operations & Head
of Global Regulatory Affairs
|
david.schull@russopartnersllc.com
|
caudet@arenapharm.com
|
858.717.2310
|
858.453.7200, ext.
1612
|
|
|
|
www.arenapharm.com
|
|
SOURCE Arena Pharmaceuticals, Inc.